Correlation Between Candel Therapeutics and Exagen

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Candel Therapeutics and Exagen at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Candel Therapeutics and Exagen into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Candel Therapeutics and Exagen Inc, you can compare the effects of market volatilities on Candel Therapeutics and Exagen and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Candel Therapeutics with a short position of Exagen. Check out your portfolio center. Please also check ongoing floating volatility patterns of Candel Therapeutics and Exagen.

Diversification Opportunities for Candel Therapeutics and Exagen

-0.34
  Correlation Coefficient

Very good diversification

The 3 months correlation between Candel and Exagen is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Candel Therapeutics and Exagen Inc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Exagen Inc and Candel Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Candel Therapeutics are associated (or correlated) with Exagen. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Exagen Inc has no effect on the direction of Candel Therapeutics i.e., Candel Therapeutics and Exagen go up and down completely randomly.

Pair Corralation between Candel Therapeutics and Exagen

Given the investment horizon of 90 days Candel Therapeutics is expected to under-perform the Exagen. But the stock apears to be less risky and, when comparing its historical volatility, Candel Therapeutics is 1.12 times less risky than Exagen. The stock trades about -0.1 of its potential returns per unit of risk. The Exagen Inc is currently generating about 0.11 of returns per unit of risk over similar time horizon. If you would invest  342.00  in Exagen Inc on September 5, 2024 and sell it today you would earn a total of  107.00  from holding Exagen Inc or generate 31.29% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Candel Therapeutics  vs.  Exagen Inc

 Performance 
       Timeline  
Candel Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Candel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.
Exagen Inc 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Exagen Inc are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting technical and fundamental indicators, Exagen displayed solid returns over the last few months and may actually be approaching a breakup point.

Candel Therapeutics and Exagen Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Candel Therapeutics and Exagen

The main advantage of trading using opposite Candel Therapeutics and Exagen positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Candel Therapeutics position performs unexpectedly, Exagen can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exagen will offset losses from the drop in Exagen's long position.
The idea behind Candel Therapeutics and Exagen Inc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Other Complementary Tools

Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated